FDA Approves Mayne’s Halobetasol Foam For Adolescents
Australian Company Strengthens Its Dermatology Portfolio With US Lexette Nod
Mayne Pharma has announced receiving US FDA approval for its Lexette (halobetasol propionate) 0.05% foam for the treatment of plaque psoriasis for use in adolescents. With Lexette, Mayne now markets more than twenty dermatology products in the US including four branded products.
You may also be interested in...
Sawai’s Upsher-Smith unit has launched three further strengths of isotretinoin capsules in the US. The company has also partnered with Australia’s Mayne Pharma on US distribution for the rivals to Sun’s Absorica dermatology brand.
Mayne Pharma intends in January to introduce novel formulations of itraconazole and halobetasol in the US; but the Australian firm has been hit in its attempt to bring the Myring generic to the US market.
Adamis has announced receiving FDA approval for Zimhi, its high-dose naloxone hydrochloride for injection, indicated for the treatment of opioid overdose. The company has partnered with US WorldMeds to market Zimhi by the first quarter of 2022.